2022 World Conference on Lung Cancer (ePosters)-EP08.01-071. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

EP08.01-071. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

Back to course

Pdf Summary

The study evaluated the safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). It was an open-label, nonrandomized, phase 1b study conducted between November 2019 and December 2020.<br /><br />The primary endpoint of the study was safety and tolerability. A total of 22 patients were enrolled, and all patients were included in the safety analysis set. The median age of the patients was 60.5 years, and 68.2% of them were male. The median study follow-up was 11.8 months.<br /><br />All patients experienced at least one treatment-emergent adverse event (TEAE), with a grade 3 TEAE occurring in 59.1% of patients. Treatment-related adverse events (TRAEs) of any grade and grade 3 were reported in 95.5% and 50.0% of patients, respectively. The most commonly reported grade 3 TEAE and TRAE were hypokalemia and hypertension, respectively.<br /><br />In terms of efficacy, in the efficacy-evaluable population, the confirmed objective response rate (ORR) was 57.1% with all 12 patients achieving a partial response. The disease control rate was 85.7%. The median progression-free survival (PFS) was 11.1 months, and the median overall survival (OS) was 17.4 months.<br /><br />The combination of sitravatinib and tislelizumab showed promising antitumor activity with a manageable safety profile in patients with PD-L1-positive, locally advanced or metastatic nonsquamous NSCLC. Higher PD-L1 staining in tumor cells correlated with an increased ORR and median PFS. A phase 3 study investigating this combination therapy in advanced NSCLC is currently ongoing.

Asset Subtitle

Jun Zhao

Meta Tag

Speaker Jun Zhao

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

sitravatinib

tislelizumab

PD-L1-positive

locally advanced

metastatic

non-small cell lung cancer

safety and efficacy

grade 3 TEAE

objective response rate

progression-free survival